Fermenta Biotech Ltd
₹ 339
3.27%
08 Jul
2:25 p.m.
About
Incorporated in 1951, Fermenta Biotech
Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
Key Points
- Market Cap ₹ 998 Cr.
- Current Price ₹ 339
- High / Low ₹ 449 / 189
- Stock P/E 13.1
- Book Value ₹ 123
- Dividend Yield 0.38 %
- ROCE 21.7 %
- ROE 23.4 %
- Face Value ₹ 5.00
Pros
- Company is expected to give good quarter
- Promoter holding has increased by 2.03% over last quarter.
Cons
- Stock is trading at 2.66 times its book value
- The company has delivered a poor sales growth of 9.98% over past five years.
- Company has a low return on equity of 3.55% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 139 | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 469 | |
| 113 | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 360 | |
| Operating Profit | 26 | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 110 |
| OPM % | 19% | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 23% |
| 3 | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 12 | |
| Interest | 5 | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 14 |
| Depreciation | 10 | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 |
| Profit before tax | 14 | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 |
| Tax % | 24% | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% |
| 10 | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | |
| EPS in Rs | 2.86 | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 |
| Dividend Payout % | 29% | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 66% |
| 5 Years: | 6% |
| 3 Years: | 72% |
| TTM: | 552% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 5% |
| 3 Years: | 21% |
| 1 Year: | 64% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 |
| Reserves | 130 | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 |
| 65 | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | |
| 61 | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | |
| Total Liabilities | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 |
| 87 | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | |
| CWIP | 36 | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 |
| Investments | 17 | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 |
| 118 | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 371 | |
| Total Assets | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 | 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 | |
| -25 | -18 | -13 | 7 | -101 | -97 | -44 | -41 | -26 | -55 | -16 | -0 | |
| 13 | 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | -41 | -91 | -51 | |
| Net Cash Flow | 2 | -2 | 1 | -4 | 47 | 6 | -57 | 21 | -4 | 19 | -1 | -10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 |
| Inventory Days | 149 | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 |
| Days Payable | 120 | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 |
| Cash Conversion Cycle | 136 | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 188 |
| Working Capital Days | 73 | 4 | 20 | 115 | 90 | 97 | 202 | 171 | 180 | 123 | 108 | 114 |
| ROCE % | 9% | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20h - Of investor meeting, under the SEBI (LODR), Regulations 2015
-
Closure of Trading Window
27 Jun - Trading window closed from July 1, 2025, till 48 hours after Q1 financial results announcement.
- Announcement under Regulation 30 (LODR)-Investor Presentation 4 Jun
-
Clarification On Record Date
29 May - Record date fixed as August 6, 2025 for FY 2024-25 final equity dividend payment.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - Newspaper publication - Annual financial results for the year ended March 31, 2025
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Jun 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
Jul 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Sep 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jul 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Dec 2020Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Dec 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
Business Overview:[1][2]
a) FBL is engaged in development
and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries. It is a global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
b) Company is involved in manufacturing
of APIs for muscle relaxant and anti-flatulent applications. It delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment & management.
c) Also, company has strategic investments in subsidiaries / associate companies primarily dealing in manufacturing and marketing bulk drugs and providing services of sporting and health awareness activities / education activities.
d) Company also deals in lease rental business for ITES properties developed in Than